Urinary myeloid IgA Fc alpha receptor (CD89) and transglutaminase-2 as new biomarkers for active IgA nephropathy and henoch-Schönlein purpura nephritis

BBA Clinical

Volumn 5, Issue , 2016, Pages 79-84

  Moresco, Rafael N ^a,b   Speeckaert, Marijn M ^b   Zmonarski, Slawomir C ^c   Krajewska, Magdalena ^c   Komuda Leszek, Ewa ^d   Perkowska Ptasinska, Agnieszka ^d   Gesualdo, Loreto ^e   Rocchetti, Maria T ^e   Delanghe, Sigurd E ^b   Vanholder, Raymond ^b   Van Biesen, Wim ^b   Delanghe, Joris R ^b  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e UNIVERSITY OF BARI   (Italy)

Author keywords

Henoch Sch nlein purpura nephritis; IgA nephropathy; Myeloid IgA Fc alpha receptor; Transglutaminase 2

Indexed keywords

AZATHIOPRINE; CD71 ANTIGEN; CREATININE; CYCLOSPORIN; IMMUNOGLOBULIN A; MYCOPHENOLATE MOFETIL; MYELOID IGA FC ALPHA RECEPTOR; PEPTIDES AND PROTEINS; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; ANAPHYLACTOID PURPURA; ARTICLE; BIOCHEMICAL ANALYSIS; CLINICAL EVALUATION; ENZYME ACTIVITY; FEMALE; GLOMERULUS FILTRATION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; QUANTITATIVE ANALYSIS; REMISSION; TREATMENT OUTCOME; URINALYSIS;

EID: 84959325252     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2016.02.002     Document Type: Article

References (40)

1. Floege J., Moura I.C., Daha M.R. New insights into the pathogenesis of IgA nephropathy. Semin. Immunopathol. 2014, 36:431-442.
2. Narita I., Gejyo F. Pathogenetic significance of aberrant glycosylation of IgA1 in IgA nephropathy. Clin. Exp. Nephrol. 2008, 12:332-338.
3. Floege J. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches?. Am. J. Kidney Dis. 2011, 58:992-1004.
4. Sanders J.T., Wyatt R.J. IgA nephropathy and henoch-Schönlein purpura nephritis. Curr. Opin. Pediatr. 2008, 20:163-170.
5. Kiryluk K., Moldoveanu Z., Sanders J.T., Eison T.M., Suzuki H., Julian B.A., et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and henoch-Schönlein purpura nephritis. Kidney Int. 2011, 80:79-87.
6. Appel G.B., Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 2006, 69:1939-1944.
7. Rocchetti M.T., Centra M., Papale M., Bortone G., Palermo C., Centonze D., et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 2008, 8:206-216.
8. Meadow S.R., Scott D.G. Berger disease: henoch-Schönlein syndrome without the rash. J. Pediatr. 1985, 106:27-32.
9. Waldo F.B. Is henoch-Schönlein purpura the systemic form of IgA nephropathy?. Am. J. Kidney Dis. 1988, 12:373-377.
10. Mestecky J., Tomana M., Moldoveanu Z., Julian B.A., Suzuki H., Matousovic K., et al. Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press. Res. 2008, 31:29-37.
11. Novak J., Moldoveanu Z., Renfrow M.B., Yanagihara T., Suzuki H., Raska M., et al. IgA nephropathy and henoch-schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells. Contrib. Nephrol. 2007, 157:134-138.
12. Suzuki H., Fan R., Zhang Z., Brown R., Hall S., Julian B.A., et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest. 2009, 119:1668-1677.
13. Delanghe S.E., Speeckaert M.M., Segers H., Desmet K., Vande Walle J., Laecke S.V., et al. Soluble transferrin receptor in urine, a new biomarker for IgA nephropathy and henoch-Schönlein purpura nephritis. Clin. Biochem. 2013, 46:591-597.
14. Monteiro R.C., Moura I.C., Launay P., Tsuge T., Haddad E., Benhamou M., et al. Pathogenic significance of IgA receptor interactions in IgA nephropathy. Trends Mol. Med. 2002, 8:464-468.
15. Ben Mkaddem S., Rossato E., Heming N., Monteiro R.C. Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives. Autoimmun. Rev. 2013, 12:666-669.
16. Berthelot L., Papista C., Maciel T.T., Biarnes-Pelicot M., Tissandie E., Wang P.H., et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J. Exp. Med. 2012, 209:793-806.
17. Moresco R.N., Speeckaert M.M., Delanghe J.R. Diagnosis and monitoring of IgA nephropathy: the role of biomarkers as an alternative to renal biopsy. Autoimmun. Rev. 2015, 14:847-853.
18. van der Boog P.J., van Zandbergen G., De Fijter J.W., Klar-Mohamad N., van Seggelen A., Brandtzaeg P., et al. Fc alpha RI/CD89 circulates in human serum covalently linked to IgA in a polymeric state. J. Immunol. 2002, 168:1252-1258.
19. Leung J.C., Tsang A.W., Chan D.T., Lai K.N. Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells. J. Am. Soc. Nephrol. 2000, 11:241-249.
20. Moura I.C., Arcos-Fajardo M., Sadaka C., Leroy V., Benhamou M., Novak J., et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J. Am. Soc. Nephrol. 2004, 15:622-634.
21. Monteiro R.C. Pathogenic role of IgA receptors in IgA nephropathy. Contrib. Nephrol. 2007, 157:64-69.
22. Moura I.C., Benhamou M., Launay P., Vrtovsnik F., Blank U., Monteiro R.C. The glomerular response to IgA deposition in IgA nephropathy. Semin. Nephrol. 2008, 28:88-95.
23. Galla J.H. IgA nephropathy. Kidney Int. 1995, 47:377-387.
24. Barbour S.J., Espino-Hernandez G., Reich H.N., Coppo R., Roberts I.S., Feehally J., et al. The MEST score provides earlier risk prediction in IgA nephropathy. Kidney Int. 2015, 10.1038/ki.2015.322.
25. Counahan R., Winterborn M.H., White R.H., Heaton J.M., Meadow S.R., Bluett N.H., et al. Prognosis of henoch-Schönlein nephritis in children. Br. Med. J. 1977, ii:11-14.
26. Mohey H., Laurent B., Mariat C., Berthoux F. Validation of the absolute renal risk of dialysis/death in adults with IgA nephropathy secondary to henoch-Schönlein purpura: a monocentric cohort study. BMC Nephrol. 2013, 14:169.
27. Orsonneau J.L., Douet P., Massoubre C., Lustenberger P., Bernard S. An improved pyrogallol red-molybdate method for determining total urinary protein. Clin. Chem. 1989, 35:2233-2236.
28. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009, 150:604-612.
29. Wyatt R.J., Julian B.A. IgA nephropathy. N. Engl. J. Med. 2013, 368:2402-2414.
30. Julian B.A., Wittke S., Haubitz M., Zürbig P., Schiffer E., McGuire B.M., et al. Urinary biomarkers of IgA nephropathy and other IgA associated renal diseases. World J. Urol. 2007, 25:467-476.
31. Suzuki Y., Suzuki H., Makita Y., Takahata A., Takahashi K., Muto M., et al. Diagnosis and activity assessment of immunoglobulin A nephropathy: current perspectives on noninvasive testing with aberrantly glycosylated immunoglobulin A-related biomarkers. Int. J. Nephrol. Renov. Dis. 2014, 7:409-414.
32. Kawasaki Y. The pathogenesis and treatment of pediatric henoch-Schönlein purpura nephritis. Clin. Exp. Nephrol. 2011, 15:648-657.
33. Launay P., Grossetête B., Arcos-Fajardo M., Gaudin E., Torres S.P., Beaudoin L., et al. Fc alpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). evidence for pathogenic soluble receptor-iga complexes in patients and CD89 transgenic mice. J. Exp. Med. 2000, 191:1999-2009.
34. Tissandié E., Morelle W., Berthelot L., Vrtovsnik F., Daugas E., Walker F., et al. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int. 2011, 80:1352-1363.
35. Westerhuis R., Van Zandbergen G., Verhagen N.A., Klar-Mohamad N., Daha M.R., van Kooten C. Human mesangial cells in culture and in kidney sections fail to express Fc alpha receptor (CD89). J. Am. Soc. Nephrol. 1999, 10:770-778.
36. van der Boog P.J., De Fijter J.W., Van Kooten C., Klar-Mohamad N., Oortwijn B., Bos N.A., et al. Complexes of IgA with FcalphaRI/CD89 are not specific for primary IgA nephropathy. Kidney Int. 2003, 63:514-521.
37. Grossetête B., Launay P., Lehuen A., Jungers P., Bach J.F., Monteiro R.C. Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int. 1998, 53:1321-1335.
38. Shweke N., Boulos N., Jouanneau C., Vandermeersch S., Melino G., Dussaule J.C., et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar Collagen through TGF-beta activation and cell infiltration. Am. J. Pathol. 2008, 173:631-642.
39. Chou C.Y., Streets A.J., Watson P.F., Huang L., Verderio E.A., Johnson T.S. A crucial sequence for transglutaminase type 2 extracellular trafficking in renal tubular epithelial cells lies in its N-terminal beta-sandwich domain. J. Biol. Chem. 2011, 286:27825-27835.
40. Chen N.X., O'Neill K., Chen X., Kiattisunthorn K., Gattone V.H., Moe S.M. Transglutaminase 2 accelerates vascular calcification in chronic kidney disease. Am. J. Nephrol. 2013, 37:191-198.